The Effectiveness of Meloxicam Adjuvant Therapy to Improve Cognitive Function of Schizophrenic Patients
Downloads
Highlights:
1. Schizophrenic patients have cognitive dysfunction.
2. Meloxicam, as an adjuvant therapy, can improve cognitive function in schizophrenic patients.
Abstract
Introduction: Schizophrenia is a chronic psychotic disorder triggered by genetic and environmental factors such as an inflammatory response. The inflammatory response in schizophrenic patients increases with cognitive decline. Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) group with Cyclo-oxygenase (COX-2) inhibitory activity and can suppress the production of inflammatory cytokines. This study aimed to determine the efficacy of Meloxicam as an adjuvant therapy to improve cognitive function in schizophrenic patients.
Methods: This was a quasi-experimental study using a single-blind, pretest–post-test design. The sample size in this study was 34 subjects who had met the inclusion and exclusion criteria. All samples were divided into two groups, namely the treatment group, with as many as 17 subjects receiving additional therapy with Meloxicam 15 mg/day for 4 weeks, and the control group, with 17 subjects. The score of the Schizophrenia Cognition Rating Scale (ScoRS) was assessed before and after therapy. Data analysis used SPSS 25.0. In both groups, the SCoRS score was different.
Results: In the treatment group, there was a decrease in the SCoRS score that was greater than in the control group. There was a statistically significant difference with p = 0.002 in decreasing SCoRS scores.
Conclusion: In the treatment group, there was a decrease in the SCoRS score that was greater than in the control group. There was a statistically significant difference with p = 0.002 in decreasing SCoRS scores.
Sadock BJ, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia, PA, US: Lippincott Williams & Wilkins Publishers, 2007.
Maramis MM, Sofyan Almahdy M, Atika A, et al. The Biopsychosocial-Spiritual Factors Influencing Relapse of Patients with Schizophrenia. Int J Soc Psychiatry 2022; 68: 1824–1833.
Ajami A, Abedian F, Hamzeh Hosseini S, et al. Serum TNF-α, IL-10 and IL-2 in Schizophrenic Patients Before and After Treatment with Risperidone and Clozapine. Iran J Immunol 2014; 11: 200–209.
Talreja BT, Shah S, Kataria L. Cognitive Function in Schizophrenia and Its Association with Socio-Demographics Factors. Ind Psychiatry J 2013; 22: 47–53.
Meyer U, Schwarz MJ, Müller N. Inflammatory Processes in Schizophrenia: A Promising Neuroimmunological Target for the Treatment of Negative/Cognitive Symptoms and Beyond. Pharmacol Ther 2011; 132: 96–110.
Salsabila KN, Khairina K, Djuari L. Profile of Chronic Mental Disorder Patients with or without Suicide Ideation in the Psychiatric Ward of Dr. Soetomo General Hospital, Surabaya. JUXTA J Ilm Mhs Kedokt Univ Airlangga 2021; 12: 48–53.
Na K-S, Jung H-Y, Kim Y-K. The Role of Pro-Inflammatory Cytokines in the Neuroinflammation and Neurogenesis of Schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 277–286.
Khandaker GM, Cousins L, Deakin J, et al. Inflammation and Immunity in Schizophrenia: Implications for Pathophysiology and Treatment. The Lancet Psychiatry 2015; 2: 258–270.
Putri FP, Turchan A, Fatimah N, et al. Adherence of NSAID Administration in Patients with Mild and Moderate Traumatic Brain Injury in Dr. Soetomo General Hospital, Surabaya. JUXTA J Ilm Mhs Kedokt Univ Airlangga 2021; 12: 94–97.
Lolobua MFIP, Khairina K, Wardani IAK, et al. Negative Symptoms Management in Schizophrenia. J Psikiatri Surabaya 2021; 10: 6–12.
Shafer SL, Rathmell JP, Flood P. Stoelting's Pharmacology and Physiology in Anesthetic Practice. 5th ed. Philadelphia SE -: Wolters Kluwer Health Philadelphia, 2015.
Rebhi H, Damak R, Cherif W, et al. [Impact of Duration of Untreated Psychosis on Quality of Life and Cognitive Functions]. Encephale 2019; 45: 22–26.
Sutherland M. Role of Phospholipid Hydroperoxide Glutathione Peroxidase in Hepoxilin A3 Biosynthesis in Human Platelets and Biological Actions of Hepoxilin A3 on Human Neutrophils, http://dx.doi.org/10.17169/refubium-15998 (2002).
Müller N, Krause D, Dehning S, et al. Celecoxib Treatment in an Early Stage of Schizophrenia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial of Celecoxib Augmentation of Amisulpride Treatment. Schizophr Res 2010; 121: 118–124.
Rapaport MH, Delrahim KK, Bresee CJ, et al. Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia. Biol Psychiatry 2005; 57: 1594–1596.
Furlong NE, Lovelace EA, Lovelace KL. Research Methods and Statistics: An Integrated Approach. Harcourt College Publishers, https://books.google.co.id/books?id=RyGaQgAACAAJ (2000).
Sil S, Ghosh T. Role of Cox-2 Mediated Neuroinflammation on the Neurodegeneration and Cognitive Impairments in Colchicine Induced Rat Model of Alzheimer's Disease. J Neuroimmunol 2016; 291: 115–124.
Purwono H. Pengaruh Pemberian Terapi Tambahan Meloxicam terhadap Kadar Hs-CRP dan Skor PANSS pada Pasien Skizofrenia di RSJD Arif Zainudin Surakarta. Universitas Sebelas Maret, https://digilib.uns.ac.id/dokumen/detail/58379/Pengaruh-Pemberian-Terapi-Tambahan-Meloxicam-terhadap-Kadar-Hs-Crp-dan-Skor-Panss-pada-Pasien-Skizofrenia-di-Rsjd-Arif-Zainudin-Surakarta (2018).
Aí¯d S, Bosetti F. Targeting Cyclooxygenases-1 and -2 in Neuroinflammation: Therapeutic Implications. Biochimie 2011; 93: 46–51.
Katzung BG. Basic and Clinical Pharmacology. 10th ed. Jakarta: EGC Medical Book Publisher, 2010.
Copyright (c) 2023 Nabila Nur Bilqis Islamy, I Gusti Bagus Indro Nugroho, Adriesti Herdaetha
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The formal legal aspect of journal publication accessibility refers to Creative Commons Atribution-Share Alike 4.0 (CC BY-SA).
